文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.

作者信息

Faxon David P

出版信息

Nat Rev Cardiol. 2010 Mar;7(3):124-5. doi: 10.1038/nrcardio.2009.247.

DOI:10.1038/nrcardio.2009.247
PMID:20179718
Abstract
摘要

相似文献

[1]
Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.

Nat Rev Cardiol. 2010-3

[2]
Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.

JACC Cardiovasc Interv. 2010-6

[3]
Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.

Arch Cardiovasc Dis. 2010-1-25

[4]
Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.

Nat Rev Cardiol. 2013-6

[5]
Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: En attendant Godot.

JACC Cardiovasc Interv. 2010-6

[6]
Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

Cardiovasc Ther. 2011-7-31

[7]
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Med Sci Monit. 2009-12

[8]
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?

Nat Rev Cardiol. 2009-12

[9]
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.

Clin Cardiol. 2008-3

[10]
Another view on prasugrel.

Thromb Haemost. 2009-1

引用本文的文献

[1]
G-protein-coupled receptors signaling pathways in new antiplatelet drug development.

Arterioscler Thromb Vasc Biol. 2015-3

[2]
The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.

PLoS One. 2012-12-6

本文引用的文献

[1]
Intravenous platelet blockade with cangrelor during PCI.

N Engl J Med. 2009-12-10

[2]
Platelet inhibition with cangrelor in patients undergoing PCI.

N Engl J Med. 2009-12-10

[3]
Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.

J Clin Pharmacol. 2009-9-24

[4]
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

N Engl J Med. 2009-9-10

[5]
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

J Am Coll Cardiol. 2009-7-28

[6]
Prasugrel versus clopidogrel in patients with acute coronary syndromes.

N Engl J Med. 2007-11-15

[7]
Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.

Thromb Res. 2008

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索